Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

BGB-15025 Alone and in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Participants With Advanced Solid Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04649385
Recruitment Status : Recruiting
First Posted : December 2, 2020
Last Update Posted : July 19, 2021
Sponsor:
Information provided by (Responsible Party):
BeiGene

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : August 2023
Estimated Study Completion Date : August 2024